Evidence map›Paper›PMID 31757838›Full record

Trial reportDiabetes care2020

Microvascular and Cardiovascular Outcomes According to Renal Function in Patients Treated With Once-Weekly Exenatide: Insights From the EXSCEL Trial.

M Angelyn Bethel, Robert J Mentz, Peter Merrill, John B Buse, Juliana C Chan, Shaun G Goodman, Nayyar Iqbal, Neli Jakuboniene, Brian Katona, Yuliya Lokhnygina and 7 more

Abstract readMulticenter StudyPragmatic Clinical TrialRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Diabetes care, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed, 8 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

50 citing papers in PubMed, 8 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. HbADiabetes care · 2021
    Pooled it
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Review
  14. Review
  15. Innovative Diabetes Therapies and Impact on Peripheral and Autonomic Diabetic Neuropathies: A State-of-the-Art Review.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2026
    Review
  16. Review
  17. Review
  18. Review
  19. How to individualize renoprotective therapy in obese patients with chronic kidney disease: a commentary by the Diabesity Working Group of the ERA.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2025
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

M Angelyn BethelDiabetes Trials Unit, Oxford Centre for Diabetes, Endocrinology and Metabolism, Oxford, U.K.
Robert J MentzDuke Clinical Research Institute, Duke University School of Medicine, Durham, NC.
Peter MerrillDuke Clinical Research Institute, Duke University School of Medicine, Durham, NC.
John B BuseDivision of Endocrinology, University of North Carolina School of Medicine, Chapel Hill, NC.
Juliana C ChanDepartment of Medicine and Therapeutics, The Chinese University of Hong Kong, The Prince of Wales Hospital, Shatin, Hong Kong SAR, China.ORCID 0000-0003-1325-1194
Shaun G GoodmanSt. Michael's Hospital, University of Toronto, Ontario, Canada.
Nayyar IqbalAstraZeneca Research and Development, Gaithersburg, MD.
Neli JakubonieneDepartment of Endocrinology, Lithuanian University of Health Sciences, Kaunas, Lithuania.
Brian KatonaAstraZeneca Research and Development, Gaithersburg, MD.
Yuliya LokhnyginaDuke Clinical Research Institute, Duke University School of Medicine, Durham, NC.
Renato D LopesDuke Clinical Research Institute, Duke University School of Medicine, Durham, NC.
Aldo P MaggioniANMCO Research Center, Florence, Italy.
Peter OhmanAstraZeneca Research and Development, Gaithersburg, MD.
Tsvetalina TankovaClinical Center of Endocrinology, Medical University, Sofia, Bulgaria.
George L BakrisComprehensive Hypertension Center, The University of Chicago Medicine, Chicago, IL.ORCID 0000-0003-1183-1267
Adrian F HernandezDuke Clinical Research Institute, Duke University School of Medicine, Durham, NC.
Rury R HolmanDiabetes Trials Unit, Oxford Centre for Diabetes, Endocrinology and Metabolism, Oxford, U.K. rury.holman@dtu.ox.ac.uk.ORCID 0000-0002-1256-874X

Funding

NCATS NIH HHS UL1 TR002489
6 · The paper itself

Abstract

objectiveTo evaluate the impact of once-weekly exenatide (EQW) on microvascular and cardiovascular (CV) outcomes by baseline renal function in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL). RESEARCH DESIGN AND

methodsLeast squares mean difference (LSMD) in estimated glomerular filtration rate (eGFR) from baseline between the EQW and placebo groups was calculated for 13,844 participants. Cox regression models were used to estimate effects by group on incident macroalbuminuria, retinopathy, and major adverse CV events (MACE). Interval-censored time-to-event models estimated effects on renal composite 1 (40% eGFR decline, renal replacement, or renal death) and renal composite 2 (composite 1 variables plus macroalbuminuria).

resultsEQW did not change eGFR significantly (LSMD 0.21 mL/min/1.73 m

conclusionsEQW had no impact on unadjusted retinopathy or renal outcomes. CV risk was modestly reduced only in those with eGFR ≥60 mL/min/1.73 m

Indexed as

AgedCardiovascular DiseasesCardiovascular SystemCause of DeathDiabetes Mellitus, Type 2Diabetic AngiopathiesExenatideFemaleGlomerular Filtration RateHumansKidneyMaleMicrovesselsMiddle AgedRisk FactorsSurvival AnalysisExenatide

Identifiers

PMID31757838
PMCPMC7411285

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.